Evidence map›Paper›PMID 34573384›Full record

ArticleGenes2021

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.

Elisa Baldelli, Emna El Gazzah, John Conor Moran, Kimberley A Hodge, Zarko Manojlovic, Rania Bassiouni, John D Carpten, Vienna Ludovini, Sara Baglivo, Lucio Crinò and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Mechanisms and current advances in treatingChinese medical journal pulmonary and critical care medicine · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Elisa BaldelliCenter for Applied Proteomics & Molecular Medicine, George Mason University, Manassas, VA 20110, USA.ORCID 0000-0002-6288-4599
Emna El GazzahCenter for Applied Proteomics & Molecular Medicine, George Mason University, Manassas, VA 20110, USA.ORCID 0000-0002-9312-4410
John Conor MoranCenter for Applied Proteomics & Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Kimberley A HodgeCenter for Applied Proteomics & Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Zarko ManojlovicKeck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.ORCID 0000-0001-9705-4088
Rania BassiouniKeck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
John D CarptenKeck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Vienna LudoviniDivision of Medical Oncology, S. Maria della Misericordia Hospital, 06156 Perugia, Italy.ORCID 0000-0003-2524-5824
Sara BaglivoDivision of Medical Oncology, S. Maria della Misericordia Hospital, 06156 Perugia, Italy.
Lucio CrinòDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
Fortunato BianconiIndependent Researcher, Belvedere 44, Montefalco, 06036 Perugia, Italy.ORCID 0000-0002-3132-0061
Ting DongCenter for Applied Proteomics & Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Jeremy LoffredoCenter for Applied Proteomics & Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Emanuel F PetricoinCenter for Applied Proteomics & Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Mariaelena PierobonCenter for Applied Proteomics & Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
George Mason University · USUniversity of Southern California · USAzienda Ospedaliera di Perugia · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsA549 CellsAllelesAntineoplastic AgentsBiomarkers, PharmacologicalCell Line, TumorDrug Resistance, NeoplasmExtracellular Signal-Regulated MAP KinasesGene Regulatory NetworksHumansMTOR InhibitorsMutationOncogene Protein v-aktPharmacogenomic TestingProtein Kinase InhibitorsAntineoplastic AgentsBiomarkers, PharmacologicalExtracellular Signal-Regulated MAP KinasesKRAS protein, humanMTOR InhibitorsOncogene Protein v-aktProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)drug targetKRASnon-small cell lung cancerreverse-phase protein microarrayzygosity

Identifiers

PMID34573384
PMCPMC8467269
OpenAlexW3199250627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.